MacroGenics Price To Sales Ratio vs Average Payables Analysis

MGNX Stock

USD 3.29 0.05 1.54%

MacroGenics financial indicator trend analysis is infinitely more than just investigating MacroGenics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MacroGenics is a good investment. Please check the relationship between MacroGenics Price To Sales Ratio and its Average Payables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

Price To Sales Ratio vs Average Payables

Price To Sales Ratio vs Average Payables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MacroGenics Price To Sales Ratio account and Average Payables. At this time, the significance of the direction appears to have no relationship.

The correlation between MacroGenics' Price To Sales Ratio and Average Payables is 0.0. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Average Payables in the same time period over historical financial statements of MacroGenics, assuming nothing else is changed. The correlation between historical values of MacroGenics' Price To Sales Ratio and Average Payables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of MacroGenics are associated (or correlated) with its Average Payables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Average Payables has no effect on the direction of Price To Sales Ratio i.e., MacroGenics' Price To Sales Ratio and Average Payables go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing MacroGenics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on MacroGenics sales, a figure that is much harder to manipulate than other MacroGenics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most indicators from MacroGenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.At this time, MacroGenics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 275.27 in 2024, whereas Selling General Administrative is likely to drop slightly above 37 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	275.8M	266.0M	217.2M	181.0M
Cost Of Revenue	2.7M	7.4M	8.2M	7.8M

Total Operating Expenses Cost Of Revenue

MacroGenics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.31	0.38	0.97	-0.24	0.78	-0.33	-0.58	-0.53	-0.13	0.74	0.8	0.41	0.22	0.95	0.39	0.81	0.74	0.08	0.52	0.76	0.21	0.52	0.99	-0.28	0.84
Other Current Liab	0.31		0.3	0.24	0.15	0.32	0.01	0.01	-0.28	0.2	0.07	0.33	0.13	0.08	0.25	0.21	0.16	0.5	0.23	0.2	0.3	0.31	0.25	0.29	-1.0	0.16
Total Current Liabilities	0.38	0.3		0.2	0.01	0.67	0.24	-0.02	-0.67	0.64	0.17	0.67	0.38	0.61	0.16	0.45	0.54	0.67	0.29	0.68	0.66	0.7	0.68	0.27	-0.28	0.54
Total Stockholder Equity	0.97	0.24	0.2		-0.39	0.62	-0.5	-0.66	-0.33	-0.22	0.78	0.68	0.43	0.19	0.98	0.23	0.68	0.56	-0.12	0.45	0.59	-0.04	0.37	0.98	-0.21	0.71
Other Liab	-0.24	0.15	0.01	-0.39		0.1	0.64	0.36	-0.33	-0.14	-0.23	-0.12	-0.73	-0.46	-0.31	0.37	-0.02	0.09	0.84	-0.43	0.06	0.56	0.24	-0.25	-0.16	-0.05
Property Plant And Equipment Net	0.78	0.32	0.67	0.62	0.1		0.15	-0.35	-0.72	-0.04	0.54	0.95	0.31	0.14	0.56	0.75	0.82	0.84	0.41	0.46	0.84	0.65	0.58	0.68	-0.29	0.83
Current Deferred Revenue	-0.33	0.01	0.24	-0.5	0.64	0.15		0.45	-0.36	0.23	-0.38	0.01	-0.46	-0.02	-0.54	0.67	0.04	0.18	0.58	-0.05	0.18	0.62	-0.05	-0.39	-0.01	0.04
Net Debt	-0.58	0.01	-0.02	-0.66	0.36	-0.35	0.45		-0.2	0.43	-0.93	-0.31	-0.18	0.04	-0.63	-0.12	-0.22	-0.05	0.42	-0.05	-0.08	0.27	0.06	-0.61	-0.02	-0.25
Retained Earnings	-0.53	-0.28	-0.67	-0.33	-0.33	-0.72	-0.36	-0.2		-0.3	-0.12	-0.72	-0.22	-0.34	-0.31	-0.62	-0.83	-0.89	-0.75	-0.63	-0.91	-0.81	-0.82	-0.44	0.25	-0.83
Accounts Payable	-0.13	0.2	0.64	-0.22	-0.14	-0.04	0.23	0.43	-0.3		-0.38	0.06	0.31	0.69	-0.22	-0.04	0.02	0.22	0.04	0.58	0.2	0.33	0.28	-0.17	-0.2	0.02
Cash	0.74	0.07	0.17	0.78	-0.23	0.54	-0.38	-0.93	-0.12	-0.38		0.51	0.26	0.0	0.74	0.27	0.45	0.29	-0.14	0.22	0.32	-0.08	0.23	0.76	-0.05	0.48
Non Current Assets Total	0.8	0.33	0.67	0.68	-0.12	0.95	0.01	-0.31	-0.72	0.06	0.51		0.56	0.25	0.59	0.66	0.83	0.85	0.28	0.62	0.85	0.54	0.57	0.7	-0.3	0.85
Non Currrent Assets Other	0.41	0.13	0.38	0.43	-0.73	0.31	-0.46	-0.18	-0.22	0.31	0.26	0.56		0.43	0.32	-0.05	0.35	0.35	-0.31	0.7	0.36	-0.04	0.22	0.34	-0.11	0.38
Other Assets	0.22	0.08	0.61	0.19	-0.46	0.14	-0.02	0.04	-0.34	0.69	0.0	0.25	0.43		0.16	-0.02	0.33	0.38	-0.21	0.77	0.4	0.14	0.38	0.2	-0.07	0.35
Cash And Short Term Investments	0.95	0.25	0.16	0.98	-0.31	0.56	-0.54	-0.63	-0.31	-0.22	0.74	0.59	0.32	0.16		0.13	0.66	0.54	-0.07	0.38	0.56	-0.03	0.42	0.98	-0.23	0.68
Net Receivables	0.39	0.21	0.45	0.23	0.37	0.75	0.67	-0.12	-0.62	-0.04	0.27	0.66	-0.05	-0.02	0.13		0.55	0.62	0.52	0.28	0.63	0.66	0.2	0.3	-0.19	0.58
Common Stock Total Equity	0.81	0.16	0.54	0.68	-0.02	0.82	0.04	-0.22	-0.83	0.02	0.45	0.83	0.35	0.33	0.66	0.55		0.91	0.4	0.64	0.96	0.59	0.67	0.76	-0.13	0.99
Common Stock Shares Outstanding	0.74	0.5	0.67	0.56	0.09	0.84	0.18	-0.05	-0.89	0.22	0.29	0.85	0.35	0.38	0.54	0.62	0.91		0.51	0.68	0.97	0.73	0.69	0.66	-0.48	0.91
Non Current Liabilities Total	0.08	0.23	0.29	-0.12	0.84	0.41	0.58	0.42	-0.75	0.04	-0.14	0.28	-0.31	-0.21	-0.07	0.52	0.4	0.51		0.02	0.49	0.78	0.59	0.03	-0.23	0.38
Other Current Assets	0.52	0.2	0.68	0.45	-0.43	0.46	-0.05	-0.05	-0.63	0.58	0.22	0.62	0.7	0.77	0.38	0.28	0.64	0.68	0.02		0.71	0.32	0.52	0.46	-0.18	0.67
Other Stockholder Equity	0.76	0.3	0.66	0.59	0.06	0.84	0.18	-0.08	-0.91	0.2	0.32	0.85	0.36	0.4	0.56	0.63	0.96	0.97	0.49	0.71		0.72	0.7	0.69	-0.28	0.96
Total Liab	0.21	0.31	0.7	-0.04	0.56	0.65	0.62	0.27	-0.81	0.33	-0.08	0.54	-0.04	0.14	-0.03	0.66	0.59	0.73	0.78	0.32	0.72		0.59	0.11	-0.3	0.56
Property Plant And Equipment Gross	0.52	0.25	0.68	0.37	0.24	0.58	-0.05	0.06	-0.82	0.28	0.23	0.57	0.22	0.38	0.42	0.2	0.67	0.69	0.59	0.52	0.7	0.59		0.47	-0.22	0.66
Total Current Assets	0.99	0.29	0.27	0.98	-0.25	0.68	-0.39	-0.61	-0.44	-0.17	0.76	0.7	0.34	0.2	0.98	0.3	0.76	0.66	0.03	0.46	0.69	0.11	0.47		-0.26	0.78
Short Term Debt	-0.28	-1.0	-0.28	-0.21	-0.16	-0.29	-0.01	-0.02	0.25	-0.2	-0.05	-0.3	-0.11	-0.07	-0.23	-0.19	-0.13	-0.48	-0.23	-0.18	-0.28	-0.3	-0.22	-0.26		-0.13
Common Stock	0.84	0.16	0.54	0.71	-0.05	0.83	0.04	-0.25	-0.83	0.02	0.48	0.85	0.38	0.35	0.68	0.58	0.99	0.91	0.38	0.67	0.96	0.56	0.66	0.78	-0.13

Click cells to compare fundamentals

MacroGenics Account Relationship Matchups

MacroGenics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Other Current Liab	27.1M	26.2M	24.4M	19.5M	24.2M	25.5M
Total Current Liabilities	45.2M	50.7M	74.6M	48.6M	56.1M	47.8M
Total Stockholder Equity	230.6M	295.9M	239.6M	142.0M	152.6M	199.6M
Other Liab	9.2M	6.9M	258K	59.7M	53.8M	56.5M
Property Plant And Equipment Net	48.2M	42.2M	37.7M	56.9M	45.7M	32.9M
Current Deferred Revenue	10.7M	11.4M	20.6M	69.5M	21.7M	22.3M
Net Debt	(95.9M)	(151.9M)	(98.0M)	(74.1M)	(67.0M)	(70.3M)
Retained Earnings	(642.1M)	(771.8M)	(973.9M)	(1.1B)	(1.1B)	(1.0B)
Accounts Payable	4.3M	8.0M	15.5M	4.9M	6.4M	6.1M
Cash	126.5M	181.1M	123.5M	108.9M	101.0M	146.4M
Non Current Assets Total	72.7M	66.1M	55.7M	58.3M	47.1M	40.8M
Non Currrent Assets Other	24.5M	23.9M	18.0M	(7.7M)	1.4M	1.3M
Other Assets	4.3M	23.9M	335.2M	1.4M	1.0	0.95
Cash And Short Term Investments	215.8M	272.5M	243.6M	154.3M	229.8M	224.7M
Net Receivables	12.7M	23.1M	10.4M	56.2M	10.4M	14.4M
Common Stock Total Equity	490K	562K	613K	617K	709.6K	396.0K
Common Stock Shares Outstanding	48.1M	52.4M	59.9M	61.4M	61.9M	42.1M
Liabilities And Stockholders Equity	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Non Current Liabilities Total	36.7M	32.2M	21.0M	89.8M	89.7M	94.2M
Other Current Assets	11.3M	34.0M	42.3M	10.2M	9.9M	11.0M
Other Stockholder Equity	872.2M	1.1B	1.2B	1.2B	1.3B	774.0M
Total Liab	81.9M	82.9M	95.6M	138.5M	145.8M	87.9M
Property Plant And Equipment Gross	48.2M	42.2M	110.5M	29.6M	134.1M	140.8M
Total Current Assets	239.8M	312.6M	279.6M	222.2M	251.3M	246.7M
Accumulated Other Comprehensive Income	(61K)	(3K)	16K	(7K)	(6K)	(6.3K)
Short Term Debt	3.0M	8.0M	9.4M	9.5M	3.8M	3.6M
Common Stock	490K	562K	613K	617K	621K	418.1K
Property Plant Equipment	68.4M	42.2M	37.7M	29.6M	34.0M	30.8M
Net Tangible Assets	230.6M	295.9M	239.6M	142.0M	163.3M	245.6M
Short Term Investments	89.3M	91.4M	120.1M	45.5M	128.8M	91.7M
Capital Surpluse	872.2M	1.1B	1.2B	1.2B	1.4B	817.2M
Deferred Long Term Liab	24.9M	29.3M	6.9M	59.5M	68.4M	71.8M
Net Invested Capital	230.6M	295.9M	239.6M	142.0M	152.6M	183.2M
Net Working Capital	194.6M	261.9M	205.0M	173.6M	195.2M	172.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MacroGenics Price To Sales Ratio vs Average Payables Analysis

Price To Sales Ratio vs Average Payables

Price To Sales Ratio vs Average Payables Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Average Payables

MacroGenics fundamental ratios Correlations

MacroGenics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MacroGenics fundamental ratios Accounts

Also Currently Popular

Additional Tools for MacroGenics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Total Equity
Cash And Short Term Investments	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Short Term Debt	- 1.0	Other Current Liab
Cash	- 0.93	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Common Stock	- 0.83	Retained Earnings
Common Stock Total Equity	- 0.83	Retained Earnings